Navigation Links
Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease
Date:10/22/2013

ALISO VIEJO, Calif., Oct. 22, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in study AVR-133. The study is a proof of concept, Phase II clinical trial investigating the use of AVP-923 for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease (PD).

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

"This is an important study of a compound with multifaceted pharmacology for the management of levodopa induced dyskinesia in Parkinson's disease," said Anthony E. Lang, MD, Professor and Director of the Division of Neurology and Chair for Parkinson's Disease Research at the University of Toronto. "Despite advances in PD therapeutics, many patients still suffer with poorly controlled dyskinesias, especially as they require higher doses of medications to increase dopamine levels. Dyskinesias can not only be disabling but may also limit the dose of effective medications that treat core symptoms of PD."

Top line data for this study is expected in the second half of calendar 2014.

About the Study

This proof-of-concept, double blind, randomized, crossover study will compare AVP-923 (45 mg of dextromethorphan / 10 mg of quinidine) with placebo for treatment of LID. The study will enroll approximately 16 PD patients across three study centers in the US and Canada. Study participants will receive, in a random order, a 2-week treatment with AVP-923 and a 2-week placebo treatment, separated by a 2-week break. At the end of each 2-week treatment period, patients will receive a 2-hour levodopa infusion to test the drug effect on dyskinesia. Patients will be carefully monitored throughout the 6-week
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
2. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
3. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
4. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
5. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
6. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
7. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
8. Avanir Pharmaceuticals to Participate in Two Conferences in August
9. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
11. Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® ... Alpine™ Hip Stem, the latest addition to its ... Stem is intended for use in total hip ... http://photos.prnewswire.com/prnh/20140830/141676 Alpine was ... stem philosophy. ODEV,s engineers worked closely with a ...
(Date:9/2/2014)... September 2, 2014 Today, Analysts ... WLP ), Tekmira Pharmaceuticals Corporation (NASDAQ: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,WellPoint Inc. Research Reports ,WellPoint Inc. (WellPoint) posted on ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The Australian ... universal healthcare coverage and good access to facilities ... and its associated disease burden, well-defined regulatory guidelines, ... of a new manufacturing policy will drive the ... a focus on generic substitution and price cuts ...
Breaking Medicine Technology:Ortho Development Receives FDA Clearance for Alpine Hip Stem 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5
... YORK, Dec. 23, 2010 Dr. David Samadi, robotic ... of Urology, and Chief of Robotics and Minimally Invasive Surgery ... continues to break barriers by sharing his robotic surgery ... worldwide. Today, Samadi, a pioneer surgeon in the field of ...
... 23, 2010 Generex Biotechnology Corporation ( www.generex.com ) (OTC ... to extend the closing date of its previously announced acquisition ... www.globalmeddirect.com ) to June 1, 2011. The Company ... decision of the Nasdaq Listing and Hearing Review Council affirming ...
Cached Medicine Technology:Robotic Surgery Expert Dr. David Samadi, MD Travels to Israel to Perform a Live Robotic Prostatectomy 2Robotic Surgery Expert Dr. David Samadi, MD Travels to Israel to Perform a Live Robotic Prostatectomy 3Generex Announces Extension of Global Medical Direct Acquisition Closing Date 2Generex Announces Extension of Global Medical Direct Acquisition Closing Date 3
(Date:9/2/2014)... patient adherence to treatment following a myocardial infarction ... results reported at the European Society of Cardiology,s ... Principal Investigator Valentin Fuster, MD, PhD, Director of ... at Mount Sinai and General Director of the ... in Madrid, Spain, the novel fixed-dose combination drug ...
(Date:9/2/2014)... Obesity is associated with many health risks, including heart ... found a possible way to mitigate one often-overlooked risk: ... study led by Sheldon H. Jacobson, a professor of ... obesity rates are associated with a decrease in seatbelt ... laws are in effect. , "Primary seatbelt laws lead ...
(Date:9/2/2014)... Betmiga) has been approved since December 2012 for the ... benefit assessment pursuant to the Act on the Reform ... Institute for Quality and Efficiency in Health Care (IQWiG) ... over the appropriate comparator therapy specified by the Federal ... regard to side effects: Dry mouth was less common ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Welcome to ... the over 4.6 million Canadians living with the disease, ... “Voices of Arthritis” video series featuring well-known Canadians from ... ,      Lloyd Robertson , veteran news ... silver medal skier ,      Amy Cotton ...
(Date:9/2/2014)... has become an increasing concern to health officials both ... City Department of Health and Mental Hygiene, the number ... triple the number of such deaths in 2000. Much ... rise in nonmedical prescription opioid (PO) use among teens ... among youth who transitioned from POs to heroin. ...
Breaking Medicine News(10 mins):Health News:New polypill increases heart attack patients' medication adherence 2Health News:New polypill increases heart attack patients' medication adherence 3Health News:Seatbelt laws encourage obese drivers to buckle up 2Health News:Mirabegron for overactive bladder: Added benefit not proven 2Health News:Mirabegron for overactive bladder: Added benefit not proven 3Health News:‘Voices of Arthritis’ Launches Awareness Month 2Health News:‘Voices of Arthritis’ Launches Awareness Month 3Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3
... John Brumby today announced a $100 million (AUD) ... supercomputer facility to assist in discovering cures and ... brain disorders and ,flu pandemics. , In making ... at UC San Diego, Premier Brumby said the ...
... RICHMOND, Calif., June 18 Transcept,Pharmaceuticals, Inc. today ... Officer, will present at the Jefferies 2nd Annual,Healthcare ... 25, 2008 at 9:30,AM Eastern Time., The ... http://www.wsw.com/webcast/jeff26/transcept ., About Transcept Pharmaceuticals, Transcept ...
... Accuray,Incorporated (Nasdaq: ARAY ), a global leader ... and chief executive officer, Euan S.,Thomson, Ph.D., is scheduled ... 26, 2008 at 10:15 a.m. EDT (7:15 a.m. PDT)., ... available online from the,investor relations page of the Company,s ...
... 18 The Quantum Group,Inc. (Amex: QGP ) ... for the second quarter of fiscal 2008 ended April ... 2008, the Company reported an increase,in revenues of approximately ... of fiscal year 2007. On a sequential basis compared ...
... FORT LAUDERDALE, Fla., June 18 eDiets.com,Inc. (Nasdaq: ... to bring diet,fitness and healthy lifestyle solutions to ... Information Officer effective immediately.,Bringing over 8 years of ... as the CIO and VP of IT at ...
... leader in,providing automated, molecular testing solutions, announced today ... for Human papillomavirus. Patent No.1,499 749 B1, "Human ... method for detecting the presence of HPV using ... of our collaboration with Dr. Erik,Thunnissen, a prominent ...
Cached Medicine News:Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 2Health News:Premier Brumby announces plans to build largest life sciences supercomputer facility 3Health News:Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference 2Health News:Accuray Incorporated's CEO to Speak at Jefferies Second Annual Healthcare Conference 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 2Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 3Health News:The Quantum Group Announces Second Quarter Financial Results for Fiscal Year 2008 4Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 2Health News:eDiets.com(R) Appoints New Chief Information Officer Laura Klein 3
... The 8600 Series Tabletop/Portable Digital ... universal tool for patient monitering. ... monitoring, the 8600 has earned ... worldwide and is recognized for ...
Halogen-free immersion oil based on ester oil....
Immersion oil composed on polyester polyol, diphenyl cresyl phosphate and tricyclodecane dimethanol....
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
Medicine Products: